Ligands Modified by Circular Permutation as Agonists and Antagonists

Abstract

The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof.

1 - 15 . (canceled) 
     
     
         16 . A fusion polypeptide comprising a first polypeptide fusion partner linked to a modified ligand corresponding to all or a portion of a native ligand of a target receptor, wherein the modified ligand has been circularly permuted to create a new N-terminus and a new C-terminus as compared to the native ligand, wherein the new C-terminus and the new N-terminus of the modified ligand do not disrupt any binding domain of the modified ligand for the target receptor, wherein the modified ligand is circularly permuted IL-2, the fusion partner is IL-2Rα and the target receptor is IL-2Rβγ, wherein the fusion polypeptide is optionally further fused to the Fc region of an antibody. 
     
     
         17 . The fusion polypeptide of  claim 16 , wherein the modified ligand is a circularly permuted IL-2 having a C145S mutation. 
     
     
         18 . A pharmaceutical composition comprising the fusion polypeptide of  claim 16 . 
     
     
         19 . A pharmaceutical composition comprising the fusion polypeptide of  claim 17 . 
     
     
         20 . A method of selectively agonizing IL-2Rβγ on a cell comprising contacting the cell with a fusion polypeptide of  claim 16 . 
     
     
         21 . The method of  claim 20 , wherein the fusion polypeptide is contacted with the cell extracorporeally. 
     
     
         22 . A method of selectively agonizing IL-2Rβγ on a cell comprising contacting the cell with a fusion polypeptide of  claim 17 . 
     
     
         23 . The method of  claim 22 , wherein the fusion polypeptide is contacted with the cell extracorporeally. 
     
     
         24 . The fusion polypeptide of  claim 16 , wherein the fusion polypeptide is further fused to the Fc region of an antibody.